

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Naltrexone-bupropion (prolonged release) for managing
overweight and obesity**

Batch 36

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues have been identified during the draft scope consultation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

There's no need for committee to address any, as there were none identified.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

There have been no changes made the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No stakeholders identified any equality issues.

Approved by Associate Director (name):Janet Robertson.....

Date: 26 October 2016